A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
To estimate the antitumor efficacy of dolastatin-10 in patients with measurable recurrences of platinum-sensitive ovarian carcinoma and to determine the nature and degree of toxicity of dolastatin-10 in these patients. Patients received dolastatin-10 400 microg/m(2) intravenously every 3 weeks and tumor measurements were performed every one to two cycles. Of 28 patients evaluable for response, there were no complete or partial responses. Seven patients had stable disease and 21 patients had increasing disease. Dolastatin-10 has minimal activity in recurrent platinum-sensitive ovarian carcinoma at the dose and schedule tested.